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Abstract. We report a novel in vivo spectral imaging approach to cancer detection and chemotherapy assessment.
We describe and characterize a ratiometric spectral imaging and analysis method and evaluate its performance
for tumor detection and delineation by quantitatively monitoring the specific accumulation of targeted gallium
corrole (HerGa) into HER2-positive (HER2+) breast tumors. HerGa temporal accumulation in nude mice bearing
HER2+ breast tumors was monitored comparatively by a. this new ratiometric imaging and analysis method;
b. established (reflectance and fluorescence) spectral imaging; c. more commonly used fluorescence intensity
imaging. We also tested the feasibility of HerGa imaging in vivo using the ratiometric spectral imaging method
for tumor detection and delineation. Our results show that the new method not only provides better quantitative
information than typical spectral imaging, but also better specificity than standard fluorescence intensity imaging,
thus allowing enhanced in vivo outlining of tumors and dynamic, quantitativemonitoring of targeted chemotherapy
agent accumulation into them. C©2011 Society of Photo-Optical Instrumentation Engineers (SPIE). [DOI: 10.1117/1.3589299]
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1 Introduction
Breast cancer is the most common cancer in women, and those
diagnosed with HER2+ tumors suffer from a more aggres-
sive type of breast cancer that is less responsive to standard
interventions.1 For decades, in order to reduce mortality, ef-
forts have focused on new approaches for breast tumor treat-
ment (especially chemotherapy) and its early detection.2 We
recently introduced optical imaging in vivo for chemotherapy
assessment,3 and reported that a tumor-targeted gallium cor-
role (HerGa), comprising sulfonated gallium corrole (S2Ga)
complexed with the recombinant tumor-targeting cell penetrat-
ing protein, HerPBK10, is highly effective for killing HER2+
breast cancer cells in vitro4 as well as for tumor detection
and treatment in an animal model of HER2+ breast cancer.5
In those studies, we used fluorescence intensity imaging to
validate the tumor-targeting capability of HerGa in vivo and
ex vivo. However, during the fluorescence intensity imaging of
HerGa, the blue light used for its excitation also produced sig-
nificant autofluorescence, and the penetration depths of the light
were limited to a few millimeters. Furthermore, the nonhomo-
geneous in vivo accumulation of HerGa introduced artifacts.
These limitations resulted in reduced contrast in the quanti-
tative analysis for monitoring of preferential accumulation of
HerGa and tumor detection in vivo.5 For successful translation
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of HerGa chemotherapy into the clinic, we need to improve
the contrast and the accuracy in the imaging-based monitoring
of HerGa for tumor detection. This challenge motivated an ef-
fort to develop new methods with improved quantification and
specificity.
Spectral imaging has been widely utilized as a useful quanti-
tative method in biomedical research such as functional imaging
of brain oxygenation,6 melanoma evaluation,7 and determining
the targeting capacity of molecules to specific tissues in vivo.8
In typical spectral imaging, spectral signatures are generally
analyzed by various classification techniques such as Euclidean
distance, correlation, and spectral angle measurements, resulting
in a classified image that can provide quantitative discrimina-
tion between signals from molecules of interest and unwanted
signals, with high sensitivity and specificity.9 However, when
the molecules are administered intravenously (i.v.), standard
spectral imaging and analysis may not be best suited to rapidly
determine whether the molecules are preferentially accumulated
into targeted tissues, since fast detection of these fluorophores at
the locations of interest needs to occur over a significant back-
ground signal originating from the same molecules distributed
nonspecifically (and over the whole mouse) through blood ves-
sels, within a few minutes. Applying a straightforward spectral
classification would therefore, under these circumstances, yield
low specificity results, certainly until the nontargeted molecules
are cleared from their body. Therefore, the implementation of
these methods is hampered by inherent limitations.
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Fig. 1 Construction of composite spectra with varying ratios of spectra of autofluorescence and HerGa fluorescence: the pure spectral signatures of
autofluorescence and HerGa fluorescence were obtained from the image cube before (upper-left) and after i.t. injection (upper-right). The ratiometric
spectral imaging program generates the reference spectral signatures shown in the lower images with the pure spectral signatures.
We present here a novel in vivo ratiometric spectral imag-
ing and analysis method that allows us to both monitor the
specific accumulation of a novel chemotherapy molecule into
breast tumors quantitatively and fast detect/delineate the tumors
by the drug molecule. HerGa was chosen for these investi-
gations because in addition to its chemotherapeutic effect for
HER2+ breast tumor elimination, it is also an excellent fluo-
rophore due to its intense fluorescence emission.5 In the work
described here, HerGa distribution over the nude mouse after
its i.v. injection was monitored by using both the typical spec-
tral imaging and analysis method and the ratiometric spectral
imaging and analysis at different points in time, and then the
outcomes were compared. In addition, we tested whether the ra-
tiometric spectral imaging and analysis using HerGa can allow
detection and delineation of the breast tumors. In the ratiometric
spectral imaging and analysis, five reference spectral signatures
were constructed by composite spectra with varying ratios of
pure spectral signatures of autofluorescence and HerGa fluores-
cence using a program we developed. For spectral classification,
a sum of area difference measure algorithm based on Euclidean
distance calculation was utilized.10
2 Methods and Materials
2.1 Materials
HerPBK10 protein for tumor targeting and internalization was
produced in Escherichia coli as a histidine-tagged fusion pro-
tein as described previously.11 Gallium-metallated sulfonated
corrole (S2Ga) was synthesized and combined with HerPBK10
at a molar ratio of 30:1 (based on the binding ratio of corrole
to HerPBK10 that we typically observe) and any free S2Ga re-
moved by ultrafiltration, as previously described.4 The resulting
HerGa complex was suspended in the phosphate-buffered saline
for i.v. administration (46 nmoles) in female nude mice bear-
ing HER2+ bilateral flank tumors (MDA-MB-435 tumors at
>300 mm3).5
2.2 Experimental Setup
For examination of the specific accumulation of HerGa into tu-
mor tissues, we utilized the spectral imaging mode in our multi-
mode optical imaging system as described elsewhere.12 For the
excitation of HerGa, femtosecond (fs) pulsed laser light tuned
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to 424 nm at a repetition rate of 80 MHz, was generated by
the second harmonic of a fs pulsed laser at 848 nm (Mai-Tai
Ti-Sapphire laser, Spectra-Physics). Also, we utilized an
acousto-optic tunable filter (AOTF) (ChromoDynamics, Inc.)
connected with a cooled CCD camera (PIXIS 400, Princeton
Instruments) to perform sequential spectral selection of emis-
sion fluorescence from the specimen, with a 500 nm long-pass
filter placed before the AOTF to reject the excitation light.
2.3 Construction of Reference Spectral Signatures
for Ratiometric Spectral Imaging and Analysis
For the ratiometric spectral imaging and analysis, we con-
structed reference spectral signatures with varying ratios of pure
spectral signatures of autofluorescence and HerGa fluorescence,
respectively. In order to construct the pure spectral signatures,
10 sequential images were recorded within the spectral range of
500 to 680 nm with a step size of 20 nm and a bandwidth of
10 nm before and after the HerGa intratumoral (i.t.) injection.
Then, spectral signatures of the autofluorescence and HerGa
fluorescence were generated from the sequential images of a
mouse using our custom-developed software.13 We used two
mice to construct reference spectral signatures, and selected a
relatively large area for determining the spectral signatures of
tissue autofluorescence and HerGa fluorescence (Fig. 1). While
the spectral signature of autofluorescence (A) has a peak around
520 nm and decreases as the wavelength increases, the spectral
signature of HerGa (H) has a peak around 620 nm, as shown in
Fig. 1.
In realistic in vivo situations, the fluorescence from a nude
mouse after i.v. injection of HerGa can be represented by the
linear superposition of the two pure spectral signatures (A and
H) as:
S = a1×A + a2×H,
where S is the composite spectral signature, A and H are the
spectral signatures of autofluorescence and HerGa fluorescence
respectively, and an is the relative contribution of the signals.
Using the pure spectral signatures, we constructed five spectral
signatures with 100:0, 75:25, 50:50, 25:75, and 0:100 ratios of
A and H for spectral classification. The ratio indicates a relative
HerGa contribution to autofluorescence. While the 100:0 ratio
represents pure autofluorescence, the 0:100 ratio represents a
high overall contribution of HerGa to the detected fluorescence.
In contrast, the 75:25, 50:50, and 25:75 ratios represent the tran-
sition between the pure autofluorescence and the large amount of
HerGa accumulation, respectively (Fig. 1). Thus, this approach
can provide a relatively accurate quantitative estimate of the rel-
ative contribution of two sets of contributions (autofluorescence
and HerGa fluorescence) and their variation in space and time
in vivo.
2.4 Spectral Classiﬁcation
For spectral classification, we utilized a sum of area differ-
ence measure based on Euclidean distance calculation, which
we developed as a plug-in program for Image J.13 In this clas-
sification, similarity values between the constructed reference
spectral signatures and the spectral signature on each pixel of
the image were calculated using the sum of area difference
Fig. 2 Quantitative examination of HerGa accumulation into a mouse
at different time points using ratiometric and standard spectral imaging
and analysis: (a) ratiometric spectral classification using five reference
spectral signatures (right, top), (b) ratiometric spectral classification
using three reference spectral signatures (right middle), (c) standard
spectral classification (two reference signatures, right bottom), (d) flu-
orescence intensity images. Arrows indicate tumor regions.
measure algorithm, and then each pixel was assigned to the
specified spectral class. Finally, a pseudo-color display for each
class was created for a classified image.
3 Results
3.1 HerGa Tumor Preferential Accumulation and
Tumor Detection Capacity In Vivo
To monitor tumor-preferential accumulation and detection of
HerGa after i.v. administration, we acquired consecutive im-
ages of the mouse within spectral ranges from 500 to 680 nm
with a step size of 20 nm at different time points (3, 10, and
40 min after injection) using the system described earlier (total
image acquisition time: 50 s). Then, the images were analyzed
using ratiometric spectral imaging and analysis with three to
five reference spectral signatures. In addition, the images were
classified using a more traditional spectral analysis method, for
comparison. Figure 2 shows the spectral classification images,
the reference spectral signatures, and fluorescence intensity im-
ages obtained through three different methods at the time points
mentioned earlier. In the spectral signatures, the ratios represent
the relative intensity of autofluorescence and HerGa fluores-
cence. While the green pseudo-color (100:0 ratio) represents
pure autofluoresence (A.F), the fluorescence spectral signature
of highly concentrated HerGa in the mouse is represented by a
red pseudo-color. The spectral signatures displayed with a deep
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yellow, cyan, and blue colors show different ratios of relative
contribution of HerGa to autofluorescence, respectively.
In the spectral classification images shown in Fig. 2(a), tu-
mor regions (red pseudo-color) are clearly distinguished from
the nontumor regions due to preferential accumulation of HerGa
into the tumors compared to other regions at all time points com-
pared to fluorescence intensity images. This result shows that
the ratiometric spectral imaging and analysis with five reference
spectral signatures allows the determination of the preferential
tumor accumulation of HerGa, as well as discrimination be-
tween tumor and nontumor regions, quantitatively. Figure 2(b)
shows that the tumor regions are properly distinguished from
nontumor regions at 3 min. After 3 min, while the regions clas-
sified by the cyan pseudo-color (A.F: 50 and HerGa: 50) con-
tinue to shrink, the regions classified by the red pseudo-color
(A.F: 0 and HerGa: 100) are expanded over the mouse. After
40 min, nearly the entire regions of the mouse are classified by
the red pseudo-color (A.F: 0 and HerGa: 100). In contrast, the
spectral classification images obtained using a standard spectral
analysis method [Fig. 2(c)] show that the regions classified as
HerGa are considerably distributed over the mouse at 3 min.
Thus, the tumor regions are not discriminated from the nontu-
mor regions due to HerGa accumulation. Furthermore, nearly
the entire mouse is classified by the red pseudo-color (HerGa)
after 3 min. Finally, as shown in the fluorescence intensity image
[Fig. 2(d)], we could obseve the changes of HerGa distribution
across the mouse at the indicated time-points. In Fig. 2, HerGa
preferential accumulation in the tumor was observed at the ear-
lier time points whereas after 10 min, we also observe HerGa
accumulation around the liver and heart regions. However, at this
time, the fluorescence intensity imaging produces less clear dis-
crimination between tumors and nontumor regions compared to
the ratiometric spectral imaging and analysis. Therefore, these
results indicate that ratiometric spectral imaging and analysis
provides better quantification in monitoring HerGa accumula-
tion into tumors than the standard spectral imaging analysis and
fluorescence intensity imaging methods, and support the fea-
sibility of using ratiometric spectral imaging and analysis for
tumor detection and tumor accumulation of HerGa.
3.2 Quantitative Examination of HerGa
Accumulation in Tumors From Excised Tissue
The in vivo results shown previously indicate that the ratiomet-
ric spectral imaging and analysis can provide better represen-
tation for monitoring HerGa accumulation into tumors and is
likely to be useful for tumor detection. Here, we used ratiomet-
ric spectral imaging and analysis of tumors that were harvested
from mice after tumor-accumulation of HerGa. In our previous
studies, we have shown that the preferential accumulation of
HerGa in tumors could be observed using fluorescence inten-
sity imaging after the tumors were extracted from the mouse at
1 day after i.v. HerGa administration.5 Here, tumors were ex-
tracted from the mouse at the 4th day after i.v. administration
of HerGa in order to assess the extent of tumor retention and
accumulation using ratiometric spectral imaging and analysis.
Figure 3 shows the spectral classification images and the fluo-
rescence intensity image obtained by each suggested method.
While the fluorescence intensity image displays fluorescence
(HerGa + autofluorescence) from tumors [Fig. 3(d)], the
Fig. 3 The spectral classified images and fluorescence intensity image
for quantitative examination of HerGa accumulation in tumors ex vivo
obtained by using (a) ratiometric spectral classification using five ref-
erence spectral signatures, (b) ratiometric spectral classification using
three reference spectral signatures, (c) standard spectral classification,
(d) fluorescence intensity imaging (classification spectra were the same
as in Fig. 2).
spectral classification images display the classification between
HerGa and autofluorescence. In the spectral classification im-
ages, most of the tumor regions are classified as HerGa fluores-
cence, thus verifying that the fluorescence from tumor regions is
specifically emitted from HerGa. Particularly, the spectral classi-
fication image obtained by the ratiometric spectral imaging and
analysis with five reference spectral signatures [Fig. 3(a)] only
displays red and blue pseudo colored regions, which represent
the relative ratio of HerGa fluorescence and autofluorescence,
100:0 and 75:25, respectively. However, the other spectral im-
ages [Fig. 3(a) and 3(b)] do not. These findings suggest that the
ratiometric spectral imaging and analysis can provide a more
quantitative discrimination of HerGa accumulation in extracted
tumors than standard spectral imaging and analysis. Altogether,
we now verify that HerGa is still retained in the tumors even
4 days after HerGa administration, and that this tumor accumu-
lation can be quantified using the ratiometric spectral imaging
and analysis.
4 Discussion and Conclusions
In our previous study,3 we identified limitations of our fluores-
cence imaging method, which may be considered typical for
many presently used fluorophores. In particular, the 424 nm
wavelength of light used for the excitation of HerGa in vivo
produces significant autofluorescence, and its penetration depth
through the tissues is shallow (∼ millimeter), thus resulting in
relatively low contrast in the determination of the preferential
tumor-accumulation of HerGa. As shown in Fig. 2(d), we can ob-
serve the changes of HerGa accumulation in the tumor and liver
regions at the indicated time-points. However, the image con-
trast in the determination of the preferential tumor-accumulation
of HerGa also seems to be relatively low. At this point, it is im-
portant to mention that the detected fluorescence reflects the
sum of autofluorescence, fluorescence from the skin, and fluo-
rescence from tumors although the skin fluorescence comprises
a large portion of these. However, we believe that the HerGa
fluorescence from the tumors can still be detectable for the fol-
lowing reasons. First, HerGa accumulation occurred in a subcu-
taneous tumor in which typical skin thickness is approximately
400 μm.14 Second, the wavelength of fluorescence emitted
from HerGa is around 620 nm while excitation occurs at
424 nm. Given these parameters, HerGa fluorescence is more
detectable in vivo than other fluorophores with blue excitation
but exhibiting green emission.15 Indeed, we have verified this
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after i.t. injection of HerGa (data is not shown).16 Moreover, our
previous studies show, using fluorescence intensity imaging, that
HerGa is clearly accumulated in tumors.5
In this work, we show that ratiometric spectral imaging and
analysis is useful for monitoring the preferential accumulation
of HerGa into HER2+ breast tumors at sequential time points,
and is more quantitative than both standard spectral imaging
and fluorescence intensity imaging. In the ratiometric spectral
classification images [Fig. 2(a) and 2(b)], we could clearly dis-
tinguish between tumor and nontumor regions by preferential
tumor accumulation of HerGa at the earlier time points. The
results show that HerGa accumulated into tumors earlier and
more intensely than into other regions after i.v. injection. This is
likely due to a combination of HerGa binding to HER2+ cells
and enhanced tumor vascularization.17 However, in the standard
spectral classification image [Fig. 2(c)], the discrimination be-
tween tumor and nontumor regions due to HerGa accumulation
was not possible at the early time points. Moreover, in the exam-
ination of HerGa accumulation in tumors ex vivo, the ratiometric
spectral imaging and analysis also provides more quantitative
information regarding the HerGa tumor accumulation than other
methods, as shown in our in vivo study. Therefore, we conclude
that ratiometric spectral imaging and analysis enables the mon-
itoring of the accumulation of HerGa more quantitatively than
the typical spectral imaging and analysis methods, and has the
potential to detect and delineate the tumor locations in the ear-
lier time points in vivo. In addition, the quantitative capacity
of this method is increased as the number of reference spectral
signatures with varying ratios of A and H is increased.
In this study, we considered the earlier time-points since the
accumulation of HerGa in other tissues such as skin, becomes
higher at longer time-points after i.v. HerGa injection than the
indicated time-points. Eventually, the spectral signature of flu-
orescence from skin becomes similar to the spectral signature
with the ratio of autofluorescence: HerGa, 0:100, and then the
ratiometric spectral imaging and analysis, also does not allow us
to monitor any quantitative accumulation of HerGa in tissues and
discriminate between tumors and other regions as the standard
spectral imaging and analysis. In addition, the vascularization
(angiogenesis) around tumors is much richer than in other tis-
sues such as skin and surrounding muscles. This may allow for
more HerGa accumulation in the tumor at the earlier time-points
and provides better chances to detect the tumor regions using the
ratiometric spectral imaging and analysis method at the earlier
time-points. Much longer time-points, when HerGa is washed
out from the skin, may also be well suited for tumor detection
using this ratiometric spectral imaging and anaysis.
In conclusion, we have demonstrated and validated the poten-
tial of a simple in vivo ratiometic spectral imaging and analysis
method for dynamic monitoring of HerGa accumulation into
tumor regions and for tumor detection. The results suggest that
this method can provide better quantitative information than
standard ones, and better specificity than standard fluorescence
intensity imaging. In addition, this ratiometric spectral imag-
ing and analysis may be applicable to most other chemotherapy
and photodynamic therapy molecules.8, 18 Particularly, it may
be very useful for quantitative monitoring of the distribution of
drug molecules labeled with quantum dots, where blue light ex-
citation and ratiometric spectral imaging and analysis, applied
together, are less sensitive to autofluorescence and excitation
beam spectral profiles. In the clinical setting, fast and accurate
determination19 of the location of tumors is crucial for success-
ful outcomes; the ratiometric spectral imaging and analysis with
HerGa as shown here may thus be useful for speeding up tumor
detection and for topological outlining for surgical interven-
tion. Finally, translating this method into the clinic for cancer
management could pave the way for fast, accurate prognosis
and therapy, by better spatiotemporal coupling of detection and
intervention.
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